Back to Browse Journals » International Journal of Nanomedicine » Volume 9 » Issue 1

Adenosine diphosphate-decorated chitosan nanoparticles shorten blood clotting times, influencing the structures and varying the mechanical properties of the clots

Authors Chung TW, Lin PY, Wang SS, Chen YF

Received 19 November 2013

Accepted for publication 15 January 2014

Published 31 March 2014 Volume 2014:9(1) Pages 1655—1664

DOI https://doi.org/10.2147/IJN.S57855

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Tze-Wen Chung,1,3 Pei-Yi Lin,2 Shoei-Shen Wang,2 Yen-Fung Chen3

1Department of Biomedical Engineering, National Yang-Ming University, 2Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; 3Department of Chemical and Materials Engineering, National Yunlin University of Science and Technology, Yunlin, Taiwan, Republic of China

Abstract: Chitosan nanoparticles (NPs) decorated with adenosine diphosphate (ADP) (ANPs) or fibrinogen (FNPs) were used to fabricate hemostatic NPs that can shorten blood clotting time and prevent severe local hemorrhage. The structure and mechanical properties of the blood clot induced with ANP (clot/ANP) or FNP (clot/FNP) were also investigated. The NPs, ANPs, and FNPs, which had particle sizes of 245.1±14.0, 251.0±9.8, and 326.5±14.5 nm and zeta potentials of 24.1±0.5, 20.6±1.9, and 15.3±1.5 mV (n=4), respectively, were fabricated by ionic gelation and then decorated with ADP and fibrinogen. The zeta potentials and Fourier transform infrared (FTIR) spectroscopy of the NPs confirmed that their surfaces were successfully coated with ADP and fibrinogen. The scanning electron microscope (SEM) micrographs of the structure of the clot induced with "undecorated" chitosan NPs (clot/NP), clot/ANP, and clot/FNP (at 0.05 wt%) were different, after citrated bloods had been recalcified by a calcium chloride solution containing NPs, ANPs, or FNPs. This indicated that many NPs adhered on the membrane surfaces of red blood cells, that ANPs induced many platelet aggregates, and that FNPs were incorporated into the fibrin network in the clots. Measurements of the blood clotting times (Tc) of blood clot/NPs, clot/ANPs, and clot/FNPs, based on 90% of ultimate frequency shifts measured on a quartz crystal microbalance (QCM), were significantly (P<0.05) (n=4) shorter than that of a clot induced by a phosphate-buffered solution (PBS) (clot/PBS) (63.6%±3.1%, 48.3%±6.2%, and 63.2%±4.7%, respectively). The βˆ†F2 values in the spectra of frequency shifts associated with the propagation of fibrin networks in the clot/ANPs and clot/FNPs were significantly lower than those of clot/PBS. Interestingly, texture profile analysis of the compressional properties showed significantly lower hardness and compressibility in clot/NPs and clot/ANPs (P<0.05 or better) (n=4) compared with clot/PBS and clot/FNPs. Accordingly, among the hemostatic NPs, ANP substantially reduced blood clotting times, βˆ†F2 values, and compression flow properties of the clot. Hence, ANPs have potential applications for preventing severe local hemorrhage.

Keywords: hemostatic NPs, ADP, fibrinogen, compressional properties

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Use of the Microsoft Kinect system to characterize balance ability during balance training

Lim DH, Kim CY, Jung HH, Jung DY, Chun KJ

Clinical Interventions in Aging 2015, 10:1077-1083

Published Date: 30 June 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Towards a framework for treatment effectiveness in schizophrenia

Juckel G, de Bartolomeis A, Gorwood P, Mosolov S, Pani L, Rossi A, Sanjuan J

Neuropsychiatric Disease and Treatment 2014, 10:1867-1878

Published Date: 24 September 2014

Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes

Mulvey JJ, Feinberg EN, Alidori S, McDevitt MR, Heller DA, Scheinberg DA

International Journal of Nanomedicine 2014, 9:4245-4255

Published Date: 4 September 2014

Sensory disturbances, inhibitory deficits, and the P50 wave in schizophrenia

Vlcek P, Bob P, Raboch J

Neuropsychiatric Disease and Treatment 2014, 10:1309-1315

Published Date: 14 July 2014

Biological activity of lactoferrin-functionalized biomimetic hydroxyapatite nanocrystals

Nocerino N, Fulgione A, Iannaccone M, Tomasetta L, Ianniello F, Martora F, Lelli M, Roveri N, Capuano F, Capparelli R

International Journal of Nanomedicine 2014, 9:1175-1184

Published Date: 5 March 2014

Non-adherence to topical treatments for actinic keratosis

Shergill B, Zokaie S, Carr AJ

Patient Preference and Adherence 2014, 8:35-41

Published Date: 17 December 2013